{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:58:09Z","timestamp":1794855489001,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10585-023-10228-4","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T07:01:46Z","timestamp":1691564506000},"page":"457-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oncolytic intralesional therapy for metastatic melanoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Danielle K","family":"DePalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huibers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"3","key":"10228_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10434-999-0315-x","volume":"6","author":"PJ Borgstein","year":"1999","unstructured":"Borgstein PJ, Meijer S, van Diest PJ (1999) Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 6(3):315\u2013321","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10228_CR2","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1200\/JCO.2005.12.245","volume":"23","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE (2005) The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23(21):4588\u20134590","journal-title":"J Clin Oncol"},{"issue":"6","key":"10228_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma staging: evidence-based changes in the american Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472\u2013492","journal-title":"CA Cancer J Clin"},{"key":"10228_CR4","doi-asserted-by":"crossref","unstructured":"Wesslau H, Carlander A, Ny L, W\u00e4rnberg F, Olofsson Bagge R, Lindqvist Bagge AS (2022) Tumor Burden and Health-Related Quality of Life in patients with Melanoma In-Transit metastases. Cancers (Basel). 15(1)","DOI":"10.3390\/cancers15010161"},{"issue":"4","key":"10228_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","volume":"180","author":"DL Morton","year":"1974","unstructured":"Morton DL, Eilber FR, Holmes EC et al (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180(4):635","journal-title":"Ann Surg"},{"issue":"26","key":"10228_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1056\/NEJM197406272902605","volume":"290","author":"RC Bast Jr","year":"1974","unstructured":"Bast RC Jr, Zbar B, Borsos T, Rapp HJ (1974) BCG and cancer. N Engl J Med 290(26):1458\u20131469","journal-title":"N Engl J Med"},{"issue":"6","key":"10228_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jso.2930090609","volume":"9","author":"JC Robinson","year":"1977","unstructured":"Robinson JC (1977) Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 9(6):587\u2013593","journal-title":"J Surg Oncol"},{"issue":"8","key":"10228_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.20166","volume":"100","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette\u2013Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of american Joint Committee on Cancer Stage I\u2013III melanoma (E1673) a trial of the Eastern Cooperative Oncology Group. Cancer: Interdisciplinary International Journal of the American Cancer Society 100(8):1692\u20131698","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society"},{"issue":"8","key":"10228_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"26","key":"10228_CR10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516","journal-title":"N Engl J Med"},{"issue":"26","key":"10228_CR11","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"issue":"4","key":"10228_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"issue":"19","key":"10228_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377(19):1824\u20131835","journal-title":"N Engl J Med"},{"issue":"2","key":"10228_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/CMR.0000000000000719","volume":"31","author":"R Olofsson Bagge","year":"2021","unstructured":"Olofsson Bagge R, Ny L, Ascierto PA et al (2021) The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Res 31(2):181\u2013185","journal-title":"Melanoma Res"},{"issue":"25","key":"10228_CR15","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene Laherparepvec improves durable response rate in patients with Advanced Melanoma. J Clin Oncol 33(25):2780\u20132788","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"10228_CR16","doi-asserted-by":"publisher","first-page":"9553","DOI":"10.1200\/JCO.2022.40.16_suppl.9553","volume":"40","author":"MM Milhem","year":"2022","unstructured":"Milhem MM, Vanderwalde AM, Bowles TL et al (2022) Updated results from the skin cancer cohorts from an ongoing phase 1\/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). J Clin Oncol 40(16suppl):9553\u20139553","journal-title":"J Clin Oncol"},{"issue":"8","key":"10228_CR17","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1245\/s10434-019-07288-w","volume":"26","author":"JT Miura","year":"2019","unstructured":"Miura JT, Kroon HM, Beasley GM et al (2019) Long-term oncologic outcomes after isolated limb infusion for Locoregionally metastatic melanoma: an International Multicenter Analysis. Ann Surg Oncol 26(8):2486\u20132494","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10228_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642\u2013662","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"10228_CR19","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I et al (2016) Patterns of clinical response with Talimogene Laherparepvec (T-VEC) in patients with Melanoma treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol 23(13):4169\u20134177","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10228_CR20","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","volume":"25","author":"MC Perez","year":"2018","unstructured":"Perez MC, Miura JT, Naqvi SMH et al (2018) Talimogene Laherparepvec (TVEC) for the treatment of Advanced Melanoma: a Single-Institution experience. Ann Surg Oncol 25(13):3960\u20133965","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10228_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","volume":"228","author":"RJ Louie","year":"2019","unstructured":"Louie RJ, Perez MC, Jajja MR et al (2019) Real-world outcomes of Talimogene Laherparepvec Therapy: a multi-institutional experience. J Am Coll Surg 228(4):644\u2013649","journal-title":"J Am Coll Surg"},{"key":"10228_CR22","doi-asserted-by":"crossref","unstructured":"Carr MJ, Sun J, DePalo D et al (2021) Talimogene Laherparepvec (TVEC) for the treatment of Advanced Locoregional Melanoma after failure of Immunotherapy: a multi-institutional experience. Ann Surg Oncol.","DOI":"10.1245\/s10434-021-10910-5"},{"key":"10228_CR23","unstructured":"Chesney JA, Ribas A, Long GV et al (2022) Randomized, Double-Blind, Placebo-Controlled, global phase III trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma. J Clin Oncol. Jco2200343"},{"issue":"5","key":"10228_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41416-019-0530-6","volume":"121","author":"J Chesney","year":"2019","unstructured":"Chesney J, Puzanov I, Collichio F et al (2019) Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer 121(5):417\u2013420","journal-title":"Br J Cancer"},{"issue":"17","key":"10228_CR25","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F et al (2018) Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in Combination with Ipilimumab Versus Ipilimumab alone in patients with Advanced, Unresectable Melanoma. J Clin Oncol 36(17):1658\u20131667","journal-title":"J Clin Oncol"},{"issue":"10","key":"10228_CR26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","volume":"27","author":"R Dummer","year":"2021","unstructured":"Dummer R, Gyorki DE, Hyngstrom J et al (2021) Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med 27(10):1789\u20131796","journal-title":"Nat Med"},{"key":"10228_CR27","unstructured":"Replimune announces positive initial data (2022) From the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial & an RP2\/3 program update [press release], vol 7. Replimune"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10228-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:12:06Z","timestamp":1725462726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10228-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10228"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10228-4","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Given Name and Family Name of the author Roger Olofsson Bagge has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.K.D., M.C.P., and A.H. declare no conflicts of interest. R.O.B. has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag) and SkyLineDx, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD\/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme, and is a shareholder in SATMEG Ventures AB. J.S.Z. has advisory board relationships and has received fees from with Merck, Novartis, Philogen, Castle Biosciences, Pfizer, and Sun Pharma. He also received research funding from Amgen, Delcath Systems, Philogen, and Provectus. He serves on the medical advisory board for Delcath Systems.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}